About this trial
The study seeks primarily to determine whether modulation of systemic and testicular sex steroids balance by aromatase inhibitors will positively affect the metabolic health and spermatogenesis of men with Klinefelter syndrome (KFS) as compared to the current state of the art for each issue.
Secondary objectives of this study are (i) to unravel the heterogeneity of the reproductive and metabolic phenotype of men with KFS by performing a multi-omic analysis in a large cohort at baseline; (ii) to evaluate the efficacy of semaglutide-induced weight loss to achieve metabolic and reproductive benefit in men with Klinefelter syndrome as compared to standard testosterone replacement; (ii) to assess whether addition of hCG to aromatase inhibitors further increases intratesticular testosterone and promotes spermatogenesis in men with KFS.
Eligibility criteria
Qualifiers
Age range: 16-40 years old
Intention to become parent or interest in fertility preservation
Confirmed azoospermia (lack of spermatozoids) after centrifugation of one semen sample
Age range: 18-65 years old
Disqualifiers
Contraindications to testosterone-rising therapies (prostate or breast cancer, PSA > 4 µg/l, active liver disease, symptomatic heart disease)
Decreased life expectancy due to terminal disease
Known or suspected non-compliance, drug or alcohol abuse
Inability to follow the procedures of the study (language problems, severe psychological or mental disorders)
Trial design
Treatments tested in this trial
- Anastrozole
- Semaglutide
- human chorionic gonadotropin
- Testosterone gel
Treatment groups
6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Georgios Papadakis
Lead sponsor
University of Lausanne Hospitals
Sponsor institution